Polymorphic ventricular tachycardia is an abnormal heart rhythm where the bottom chambers of your heart beat too quickly. People with severe cases may experience sudden cardiac arrest. Conditions that ...
Solid Biosciences announces Phase 1b trial for SGT-501, a gene therapy for catecholaminergic polymorphic ventricular tachycardia, with FDA designations. Solid Biosciences Inc. has announced the ...
Nashville, TN - In one of the first studies to look at the long-term effects of dofetilide (Tikosyn? - Pfizer) in patients with left ventricular dysfunction and implantable cardioverter-defibrillators ...
We report a case of vasovagal syncope caused by serious ventricular arrhythmias, which were triggered by PVCs originating from the RVOT. Intravenous administration of edrophonium chloride reproducibly ...
- Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to address underlying causes of CPVT, a life-threatening, arrhythmogenic cardiac condition - - Solid ...
Researchers have developed a novel method for simultaneously recording action potentials (APs)—temporary changes in electrical potential when cells become excited—and calcium transients—calcium ...
CHARLESTOWN, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and ...
Researchers from Leiden University Medical Center (LUMC) and the Leiden-based biotech company Ncardia have joined forces to develop a new platform that enables the automated production of 3D cardiac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results